Facebook-f Instagram
Facebook-f Instagram
Book Online

Appointment Request

Appointment Request

"*" indicates required fields

This field is for validation purposes and should be left unchanged.
Are you a new or returning patient?*
Full Name*
Sex*
Consent*
Consent*
Consent*
Book Online

Appointment Request

Appointment Request

"*" indicates required fields

This field is for validation purposes and should be left unchanged.
Are you a new or returning patient?*
Full Name*
Sex*
Consent*
Consent*
Consent*

Clinical Trial Opportunities

doctor doing clinical trials

Exploring Cutting-Edge Treatment Opportunities

The doctors at Ballantyne Medical Associates® in Charlotte, North Carolina are currently offering patient participation in several clinical trials. The practice will compensate patients for their office visit, and patients usually feel good about making a positive contribution to the advancement of medical knowledge. If you’re interested in participating in any of our current clinical trials, call the Research Team at (980) 579-9706 to schedule an appointment.

Get in Touch

Clinical Trial Opportunities

Clinical trials are an excellent way to obtain access to medications that are not yet available to the general public and only available in a tightly controlled FDA regulated environment.

Additionally, unknown to many patients, are clinical trials that are designed around medications that have already been FDA approved but are now either looking for approval for additional indications or confirmation of superiority over other commercially available pharmacotherapeutic agents.

Additionally, our clinical trials have benefits such as:
  • No cost office visits - No co-pays, No deductibles.
  • No charge for trial medications, diagnostic tests or lab tests that are part of the trial design.
  • Lastly, patients often have an overall sense of improved well-being since they are contributing to the advancement of medical knowledge while at the same being compensated for their time for each office visit they attend.

We are CURRENTLY offering patient participation in the following clinical trials:

Contact Us
migraines

Adolescent Migraine:

We are currently enrolling for an Adolescent Migraines clinical trial. Participants will be compensated for their time and participation.

To qualify you must be 6-17 years old, have 1-14 migraine attacks per month typically lasting between 3 and 72 hours and have previously tried at least one oral medication for treatment. If you can relate to all the points above you may qualify!

Sample Donation:

This research study focuses on GLP-1 therapy response in patients with Type 2 Diabetes and Obesity. The aim is to understand genetic variations influencing treatment efficacy and metabolic outcomes through fresh biological samples (blood). This research aims to advance precision medicine approaches for T2DM and obesity management.

Mayo Clinical Migraine Comparison Study:

Purpose: Compare the effectiveness of three common migraine preventive medications: Atogepant, Propranolol, and Topiramate.

Goal: Determine if these medications are equally effective, which may influence how health care providers prescribe them.

Who can participate in this study?

  • Age: Be age 18 – 70 years old
  • Migraine frequency: Have at least 4 moderate to severe headache days a month
  • Migraine duration: At least one year experiencing migraines
  • Pregnancy/breastfeeding: NOT pregnant or
  • Other exclusions may apply
  • You can reach out to a Research Staff Member or your Provider

Type 2 Diabetes:

4 Upcoming Genentech Type 2 Diabetes Mellitus studies.
Enicepatide is an investigational once-weekly subcutaneous injectable, dual GLP-1/GIP receptor agonist being developed for the treatment of people living with obesity and associated comorbidities including type 2 diabetes (T2D).

* T2DM – Diet & Exercise Only
* T2DM – Inadequately Controlled on Oral Glucose-Lowering
* T2DM – Inadequately Controlled on Insulin and/or Oral Therapy
* T2DM – Insulin With or Without Oral Glucose-Lowering Medications

COPD with Type 2 Inflammation:

2 New COPD Studies with GSK:

Depemokimab is being developed as long-acting subcutaneous injectable. The aim of this study is to investigate Depemokimab as an add on therapy in patients with uncontrolled moderate to severe COPD or patients with moderate to severe COPD and an elevated risk for exacerbations. 

Showing Slide 1 of 5
Scroll to Top

Appointment Request

Appointment Request

"*" indicates required fields

This field is for validation purposes and should be left unchanged.
Are you a new or returning patient?*
Full Name*
Sex*
Consent*
Consent*
Consent*